Anticancer drugs based on alkenyl and boryl substituted titanocene complexes

The alkenyl-substituted titanocene complex [Ti(η⁵-C₅H₅)(η⁵-C₅H₄{CMe₂(CH₂CH₂CHCH₂)})Cl₂] (1) has been synthesized and characterized using traditional methods. The reaction of 1 with 9-BBN gave the boryl substituted complex [Ti(η⁵-C₅H₅)(η⁵-C₅H₄{CMe₂(CH₂CH₂CH₂CH₂BC₈H₁₄)})Cl₂] (2). The cytotoxic activity of 1 and 2 was tested against tumour cell lines human adenocarcinoma HeLa, human myelogenous leukemia K562, human malignant melanoma Fem-x, human breast carcinoma MDA-MB-361 and normal immunocompetent cells peripheral blood mononuclear cells PBMC and compared with those of the reference complexes [Ti(η⁵-C₅H₅)₂Cl₂] (R1), [Ti(η⁵-C₅H₄Me)₂Cl₂] (R2) and [Ti(η⁵-C₅H₅)(η⁵-C₅H₄SiMe₃)Cl₂] (R3). Complex 1 showed higher cytotoxic activities on HeLa, Fem-x and K562 (IC₅₀ values from 96.6 ± 3.4 to 149.2 ± 2.9 μM) than the reference complexes R1, R2 and R3 which presented IC₅₀ values from 173.3 ± 6.0 to >200 μM. On the other hand, boryl substituted complex 2, present slightly lower cytotoxic activities than 1 on HeLa, Fem-x and K562 (IC₅₀ values from 155.6 ± 5.5 to 167.9 ± 4.2 μM). However, 2 was the most active of the studied complexes against MDA-MB-361 (IC₅₀ value of 161.1 ± 0.1 μM). Structural studies based on DFT calculations of 1 and 2 have also been carried out in order to gain a possible insight into the relationship between metal complex structure and cytotoxicity.